- ►annals.org JL Chiasson, RG Josse, JA Hunt, C Palmason … - Annals of internal medicine, 1994 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To evaluate the long-term efficacy of acarbose, an -glucosidase ... Cited by 354 - Related articles - BL Direct - All 6 versions
RF Coniff, JA Shapiro, TB Seaton, GA Bray - The American Journal of Medicine, 1995 - Elsevier All active treatments were superior (P <0.05) to placebo in reducing
postprandial hyperglycemia and HbA 1c levels. The ranking in order of efficacy
was: acarbose-plus-tolbutamide, tolbutamide, acarbose, and placebo. The ... Cited by 104 - Related articles - BL Direct - All 7 versions
J Hoffmann, M Spengler - Diabetes Care, 1994 - Am Diabetes Assoc OBJECTIVE--To compare the different therapeutic principles of alpha-glucosidase
inhibitors and sulphonylureas as first-line treatment in non-insulin-dependent
diabetes mellitus (NIDDM) patients with dietary failure. RESEARCH DESIGN ... Cited by 101 - Related articles - BL Direct - All 10 versions
RF Coniff, JA Shapiro, TB Seaton, BJ … - Diabetes Care, 1995 - Am Diabetes Assoc OBJECTIVE--To determine whether a forced titration of acarbose (from 50 to 300
mg three times daily) administered over a 24-week period, in conjunction with
diet and insulin therapy, improves glycemic control and reduces daily ... Cited by 74 - Related articles - BL Direct - All 5 versions
M Hanefeld, S Fischer, J Schulze, M Spengler … - Diabetes Care, 1991 - Am Diabetes Assoc OBJECTIVE: Acarbose inhibits alpha-glucosidases of the small intestine and thus
delays glucose release from complex carbohydrates. Therefore, its efficacy and
acceptability as a first-line drug in non-insulin-dependent diabetes ... Cited by 120 - Related articles - All 6 versions
RF Coniff, JA Shapiro, D Robbins, R … - Diabetes Care, 1995 - Am Diabetes Assoc OBJECTIVE--To compare the safety and efficacy of three doses of acarbose (100,
200, and 300 mg three times daily) with placebo for the treatment of
non-insulin-dependent diabetes mellitus (NIDDM) in patients maintained on ... Cited by 107 - Related articles - BL Direct - All 6 versions
RF Coniff, JA Shapiro, TB Seaton - Archives of Internal Medicine, 1994 - archinte.highwire.org Background:Acarbose delaysthe release ofglucosefrom complex carbohydrates and
disaccharides by inhibiting intestinal \g=a\-glucosidases,attenuating
postprandial in- crements in blood glucose and insulin. This multicenter ... Cited by 60 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] DE Kelley, P Bidot, Z Freedman, B Haag, D … - Diabetes Care, 1998 - Am Diabetes Assoc It can be difficult to control postprandial hype rglycemia in patients with type
2 diabetes. Impaired insulin secretion, par- ticularly during the early prandial
phase, is a key factor in an inefficient prandial sup- p ression of ... Cited by 69 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org [PDF] RR Holman, CA Cull, RC Turner - Diabetes Care, 1999 - Am Diabetes Assoc Patients Of 3,309 patients attending UKPDS clinics (8) between May and September
1994, 1,946 (59%) agreed to take part in a 3-year, double-blind,
placebo-controlled trial of acarbose given in addition to their pre e x- ... Cited by 193 - Related articles - BL Direct - All 8 versions
LS Hermann, B Schersten, PO Bitzen, T … - Diabetes Care, 1994 - Am Diabetes Assoc OBJECTIVE--To assess and compare the therapeutic efficacy and safety of
metformin (M) and sulfonylurea (glyburide, G), alone and in various
combinations, in patients with non-insulin-dependent diabetes mellitus ... Cited by 233 - Related articles - BL Direct - All 7 versions
